narcolepsy

News

Lundbeck makes bid for Avadel, trying to displace Alkermes

Another pharma M&A fight has broken out, with Lundbeck outbidding Alkermes in an attempt to take control of Avadel Pharma and its narcolepsy product.

News

Alkermes breaks new ground in narcolepsy with orexin drug

Alkermes' alixorexton is the first orexin 2 receptor agonist to show efficacy in phase 2 trials involving patients with both main narcolepsy subtypes.

News

Alkermes bets $2.1bn on Avadel and its narcolepsy drug

Alkermes will buy Avadel Pharma and its fast-growing narcolepsy drug Lumryz in a deal valued at up to $2.1 billion.

News

Takeda's narcolepsy programme gets back on track

Takeda will move quickly ahead with regulatory filings for oveporexton as a treatment for narcolepsy after a pair of phase 3 wins.

News

Jazz pays $145m to resolve Xyrem antitrust disputes

Jazz Pharma has offered to pay $145m to settle claims it paid to prevent generic versions of its narcolepsy drug Xyrem from reaching the US market.

R&D

Competition is on the horizon for costly narcolepsy treatmen...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment.

Lundbeck makes bid for Avadel, trying to displace Alkermes

Alkermes breaks new ground in narcolepsy with orexin drug

Alkermes bets $2.1bn on Avadel and its narcolepsy drug

Takeda's narcolepsy programme gets back on track

Jazz pays $145m to resolve Xyrem antitrust disputes

Competition is on the horizon for costly narcolepsy treatmen...

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

narcolepsy

Editor's Picks